Breast cancer, a cancer that develops from the tissues of the breast, is the most common cancer in the UK. There are many types of breast cancer and they are often grouped based on the presence or absence of some specific types of proteins ('receptors') in the cells of the patient. The most common type of breast cancer are those that are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). The advanced form of the HR+ and HER2- breast cancer occurs when the cancer has spread to other parts of the body such as the bones, brain and liver.

Alpelisib is a new drug that is being developed for patients with the HR+/HER2- type of advanced breast cancer. The drug is being developed to be given in combination with fulvestrant, a drug that is already in use for the treatment of advanced breast cancer. Alpelisib targets a very specific enzyme that transmits signals to cells, stopping the growth and survival of cancer cells. Alpelisib is taken orally while fulvestrant is given by injection. If approved, the combination of both drugs will offer additional treatment options for patients with advanced HR+/HER2- breast cancer that have not responded well to other drugs.
TARGET GROUP

Breast cancer (hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), advanced, men and postmenopausal women) - first or second line; in combination with fulvestrant

TECHNOLOGY

DESCRIPTION

Alpelisib (BYL719) is a phosphatidylinositol 3-kinase (PI3K) alpha inhibitor with potential antineoplastic activity. The drug specifically inhibits PI3K alpha isoform of PI3K. Its biological activity correlates with inhibition of various downstream signalling components of the PI3K/AKT signalling pathway. This may result in inhibition of tumour cell growth and survival in breast cancer cell lines harbouring PIK3CA mutations.1,2

Fulvestrant (Faslodex) is a medication (hydroxysteroid derivative) that acts as an anti-oestrogen agent. Specifically, it binds to the oestrogen receptor with affinity comparable to that of oestradiol and down regulates the oestrogen receptor protein in human breast cancer cells (selective oestrogen receptor degrader).3

The development of alpelisib in combination with fulvestrant is under development as a treatment of men and postmenopausal women with HR+, HER2- advanced breast cancer whose cancer has progressed on or after aromatase inhibitor treatment.

In the phase III clinical trial (SOLAR-1; NCT02437318), alpelisib is administered orally at 300mg once daily in combination with fulvestrant (500mg intramuscular injection on days 1 and 15 of cycle 1 and day 1 of each subsequent cycle). Treatment duration is not reported for this trial.

Alpelisib is currently in clinical trials for non-small cell lung cancer (phase II).

The combination of alpelisib with fulvestrant does not currently have marketing authorisation in the EU for any indication. Alpelisib also does not currently have marketing authorisation in the EU for any indication.

Fulvestrant is a marketed drug in the UK/EU, indicated for the treatment of HR+, metastatic breast cancer in postmenopausal women with disease progression following anti-oestrogen therapy. It is indicated for the treatment for advanced breast cancer, with a distinct and different mode of action. Faslodex is also indicated in combination with palbociclib for the treatment of women with HR+, HER2- advanced or metastatic breast cancer whose cancer has progressed after endocrine therapy, as monotherapy for expanded use in women with HR+, HER2- advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy. Fulvestrant is formulated as injection solution for intramuscular route of administration.3 Fulvestrant is associated with adverse effects that include; urinary tract infections, reduced platelet count, hypersensitivity reactions, anorexia, headache, hot flushes, venous thromboembolism, nausea, vomiting, diarrhoea, elevated hepatic enzymes (ALT, AST, ALP), elevated bilirubin, rash, joint and musculoskeletal pain, back pain, vaginal haemorrhage, asthenia, injection site reactions, neuropathy peripheral, sciatica.4
**INNOVATION and/or ADVANTAGES**

PI3K–AKT–mTOR is the most frequently activated pathway in breast cancer. A number of PI3K inhibitors are being developed by pharmaceutical companies, including pan-PI3K inhibitors. Alpelisib is a PI3K alpha-selective inhibitor; targeting a single PI3K isoform may allow administration at therapeutic doses without being limited by toxicities associated with inhibiting multiple isoforms.\(^5\)

If licensed, alpelisib in combination with fulvestrant will offer an additional treatment option for men and postmenopausal women with HR+, HER2- advanced breast cancer whose cancer has progressed on or after aromatase inhibitor treatment.

**DEVELOPER**

Novartis Pharmaceuticals.

**PATIENT GROUP**

**BACKGROUND**

Breast cancer arises from the tissues of the breast and most commonly originates in the cells that line the ducts. There are several types of breast cancer described according to the receptors expressed on the surface of tumour cells, stage of diagnosis, and rate of growth.\(^6\) HR+ breast cancer includes disease in which tumour cells express either oestrogen receptors (ER+) or progesterone receptors (PR+).\(^7\) Approximately 80% of breast cancers in postmenopausal women are HR+ and around two-thirds of breast cancers are ER+. Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity.\(^8\) HER2 are overexpressed in around 15-25% of women with breast cancer and promote tumour growth.\(^9\) HER2 negative (HER2-) breast cancer refers to disease that does not overexpress HER2.\(^7\)

Advanced or metastatic (stage IV) breast cancer refers to disease that has spread to other parts of the body. Common sites for metastases include the bones, liver, lung and brain. The causes of breast cancer are not completely understood, however a number of factors are known to increase its likelihood, such as exposure to radiation, increased alcohol consumption, being taller, being overweight or obese, exposure to oestrogen and hormone replacement therapy, greater breast tissue density, and genetic factors. The risk of developing breast cancer is also known to increase markedly with inheritance of certain genes (e.g. BRCA2, BRCA1 and TP53).\(^10\)

Breast cancer in adults can occur at any age, though there is an increased risk in postmenopausal women, and a previous benign breast lump or diagnosis of early breast cancer further increases the risk. Breast cancer is normally characterised by a lump or thickened tissue in the breast area, however not all lumps will be cancerous. Other features include a change in breast size or shape, discharge from the nipple (which may include blood), lumps/swelling in armpits, dimples on the skin of the breast and a rash around the nipple area. Symptoms include pain in the breast or axilla and signs and symptoms can occur in one or both breasts.\(^11\)

Breast cancer patients experience physical symptoms and psychosocial distress that adversely affect their quality of life (QOL). Treatment, including chemotherapy, can cause physical and psychological problems that adversely affect patient QOL, and cancer can have other effects including anger, grief, suffering and pain.\(^12\)
**CLINICAL NEED and BURDEN OF DISEASE**

Breast cancer is the most common cancer in the UK, accounting for 15% of all newly diagnosed cancers.\(^{13}\) Breast cancer risk is strongly related to age, with almost half (48%) of breast cancer cases in the UK each year being diagnosed in people aged 65 and over (2012-2014). Incidence rates for breast cancer are projected to rise by 2% in the UK between 2014 and 2035, to 210 cases per 100,000 females by 2035.\(^{14}\)

More than 1 in 10 breast cancer cases are diagnosed at an advanced or metastatic stage in the UK. Approximately 5% of patients present with metastatic breast cancer, and around 30% of people who present with localised disease will later develop metastases. Approximately 70–80% of people with metastatic breast cancer have HER2- tumours, of which about 50% will also be HR+.\(^{14,15}\)

The hormone receptor status of the breast cancer affects prognosis. HR+ breast cancers have higher rates of survival compared to HR-negative breast cancers (breast cancer cells which do not overexpress oestrogen or progesterone receptors) at 5 years after diagnosis (1989 to 2004) at 85% vs. 69% respectively.\(^{16}\)

In England in 2015 there were 46,083 registrations of newly diagnosed cancer of the breast (ICD-10 code C50), and the directly age-standardised rate per 100,000 population was 1.4 for males and 170.2 for females. There were 9,626 registrations of death from neoplasm of the breast, and the directly age-standardised rate per 100,000 population was 0.3 for males and 34.3 for females.\(^{17}\)

In England in 2016/17 there were 207,043 finished consultant episodes (FCEs) and 85,801 FCE bed days with primary diagnosis of ICD-10 code C50 (malignant neoplasm of breast). There were 203,454 hospital admissions, of which 169,800 were day cases.\(^{18}\)

The population likely to be eligible to receive alpelisib in combination with fulvestrant could not be estimated from available published sources.

---

**PATIENT PATHWAY**

<table>
<thead>
<tr>
<th>RELEVANT GUIDANCE</th>
</tr>
</thead>
</table>

- NICE technology appraisal in development. Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen [ID1072] (GID-TA10094). Expected publication date to be confirmed.
- NICE technology appraisal in development. Ribociclib for breast cancer [ID1026] (GID-TA10141). Expected publication date to be confirmed.
- NICE technology appraisal in development. Breast cancer (HER2 negative, HR positive) - Everolimus (with exemestane, after endocrine therapy) [ID965] (GID-TA10028). Expected publication date to be confirmed.
- NICE technology appraisal in development. Palbociclib for treating hormone-receptor positive, HER2-negative breast cancer [ID916] (GID-TA10095). Expected publication date to be confirmed.
- NICE technology appraisal in development. Breast cancer (hormone-receptor positive, HER2-negative) - palbociclib [ID915] (GID-TA10068). Expected publication date to be confirmed.
- NICE technology appraisal in development. Breast cancer (brain metastases) - etirinotecan pegol [ID881] (GID-TA10066). Expected publication date to be confirmed.
- NICE technology appraisal in development. Breast cancer (HER2-positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523] (GID-TAG322). Expected publication date to be confirmed.
- NICE technology appraisal. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423). December 2016.

**NHS ENGLAND and POLICY GUIDANCE**


**OTHER GUIDANCE**


**CURRENT TREATMENT OPTIONS**

The aim of treatment for locally advanced or metastatic breast cancer is to control and slow down the spread of the cancer, relieve symptoms and give the patient the best quality of life for as long as possible. A number of treatment options exist. The most appropriate treatment will depend on factors such as where the breast cancer is in the body, how extensive it is (how many sites and how large), symptoms, previous treatments, the characteristics of the cancer (such as oestrogen receptors) and general health (and any other medical conditions) of the patient.21

NICE guidelines for managing HR+, HER2- advanced breast cancer recommend the following treatments.
Endocrine therapy or chemotherapy:

- Offer endocrine therapy as a first-line treatment for the majority of patients with HR+ advanced breast cancer.
- Offer chemotherapy as first-line treatment for patients with HR+ advanced breast cancer whose disease is imminently life-threatening or requires early relief of symptoms because of significant visceral organ involvement, providing they understand and are prepared to accept the toxicity.
- For patients with HR+ advanced breast cancer who have been treated with chemotherapy as their first-line treatment, offer endocrine therapy following the completion of chemotherapy.

**Endocrine therapy:**

- Offer an aromatase inhibitor (either non-steroidal or steroidal) to:
  - postmenopausal women with ER-positive breast cancer and no prior history of endocrine therapy
  - postmenopausal women with ER-positive breast cancer previously treated with tamoxifen.

- Offer tamoxifen and ovarian suppression as first-line treatment to premenopausal and perimenopausal women with ER-positive advanced breast cancer not previously treated with tamoxifen.

- Offer ovarian suppression to premenopausal and perimenopausal women who have previously been treated with tamoxifen and then experience disease progression.

- Offer tamoxifen as first-line treatment to men with HR+ advanced breast cancer.

**Chemotherapy:**

- On disease progression, offer systemic sequential therapy to the majority of patients with advanced breast cancer who have decided to be treated with chemotherapy.
- Consider using combination chemotherapy to treat patients with advanced breast cancer for whom a greater probability of response is important and who understand and are likely to tolerate the additional toxicity.
- For patients with advanced breast cancer who are not suitable for anthracyclines (because they are contraindicated or because of prior anthracycline treatment either in the adjuvant or metastatic setting), systemic chemotherapy should be offered in the following sequence
  - first line: single-agent docetaxel
  - second line: single-agent vinorelbine or capecitabine
  - third line: single-agent capecitabine or vinorelbine (whichever was not used as second-line treatment).

**Other second-line treatments:**

- Everolimus: Everolimus, in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced HR+, HER2- breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme.

- Fulvestrant: Fulvestrant is not recommended within its licensed indication, as an alternative to aromatase inhibitors for the treatment of oestrogen-receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women whose cancer has relapsed on or after...
adjuvant anti-oestrogen therapy, or who have disease progression on anti-oestrogen therapy. Post-menopausal women currently receiving fulvestrant within its licensed indication as an alternative to aromatase inhibitors for the treatment of oestrogen-receptor-positive, locally advanced or metastatic breast cancer whose cancer has relapsed on or after adjuvant anti-oestrogen therapy, or who have disease progression on anti-oestrogen therapy, should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Other third-line treatments:

- **Eribulin:** Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when:
  - it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
  - the company provides eribulin with the discount agreed in the patient access scheme.

This guidance is not intended to affect the position of patients whose treatment with eribulin was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.\(^\text{22}\)

### EFFICACY and SAFETY

<table>
<thead>
<tr>
<th>Trial</th>
<th>SOLAR-1, NCT02437318, EudraCT-2015-000340-42); alpelisib vs placebo, both in combination with fulvestrant; phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>Status</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Source of Information</td>
<td>Trial registry(^\text{23})</td>
</tr>
<tr>
<td>Location</td>
<td>EU (incl UK), USA, Canada and other countries</td>
</tr>
<tr>
<td>Design</td>
<td>Randomised, placebo-controlled</td>
</tr>
<tr>
<td>Participants</td>
<td>N=571 (planned); aged ≥18 years; men and postmenopausal women; breast cancer; hormone receptor positive, HER2-negative; advanced; progression on or after aromatase inhibitor treatment.</td>
</tr>
<tr>
<td>Schedule</td>
<td>Randomised to alpelisib 300mg orally once daily; or placebo 300mg orally once daily; both in combination with fulvestrant 500mg intramuscular injection on days 1 and 15 of cycle 1 and day 1 of each subsequent 28-day cycle.</td>
</tr>
<tr>
<td>Follow-up</td>
<td>Follow-up for 59 mths</td>
</tr>
<tr>
<td>Primary Outcomes</td>
<td>Progression-free survival (PFS) for patients with PIK3CA mutant status as per RECIST 1.1</td>
</tr>
<tr>
<td>Secondary Outcomes</td>
<td>• Overall survival (OS) for patients with PI3KCA mutant status (up to approx. 59 mths)</td>
</tr>
<tr>
<td></td>
<td>• Overall response rate (ORR) (up to approx. 36 mths)</td>
</tr>
<tr>
<td></td>
<td>• Time to definitive deterioration of ECOG performance status (up to approx. 36 mths)</td>
</tr>
<tr>
<td></td>
<td>• Safety and tolerability of alpelisib in combination with fulvestrant (up to approx. 37 mths)</td>
</tr>
</tbody>
</table>
- Time to 10% deterioration in global health status/QOL scale score of EORTC QLQ-C30 (up to approx. 36 mths)
- Plasma concentration-time profile of alpelisib given in combination with fulvestrant and appropriate pharmacokinetics parameters (days 8 and 15 of cycle 1, then day 1 of cycles 2,4,6,8)
- PFS based on radiology assessments and using RECIST 1.1 criteria (baseline, up to approx. 36 mths)
- Clinical benefit rate (CBR) (up to approx. 36 mths)
- Change in global health status/QOL scale score of EORTC QLQ-C30 (baseline, up to approx. 36 mths)
- Summary statistics of fulvestrant and alpelisib plasma concentrations (days 8 and 15 of cycle 1, then day 1 of cycles 2,4,6,8)
- PFS for patients with PIK3CA non-mutant status (up to approx. 36 mths)
- OS for patients with PIK3CA non-mutant status (up to approx. 59 mths)

### Key Results

- **Adverse effects (AEs)**
  - Expected reporting date
  - Estimated primary completion date reported as Jan 2018.

### Trial

**BYLieve, NCT03056755, EudraCT-2016-004586-67)**; alpelisib in combination with fulvestrant or letrozole; phase II

**Sponsor**
Novartis Pharmaceuticals

**Status**
Ongoing

**Source of Information**
Trial registry

**Location**
EU (incl UK), USA, Canada and other countries

**Design**
Non-randomised, uncontrolled

**Participants**
N=160 (planned); aged ≥18 years; breast cancer; hormone receptor positive, HER2-negative, PIK3CA mutations; advanced; progression on or after CDK 4/6 treatment with an aromatase inhibitor or fulvestrant.

**Schedule**
Patients who received any CDK 4/6 inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib 300mg orally once daily and fulvestrant 500mg intramuscular injection on days 1 and 15 of cycle 1 and day 1 of each subsequent cycle.

Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib 300mg orally once daily and letrozole 2.5mg orally once daily.

**Follow-up**
Follow-up for 25 mths

**Primary Outcomes**
The percentage of patients who are alive without disease progression as per RECIST (timeframe: date of first dose to approx. 6 mths)

**Secondary Outcomes**
- Progression-free survival (PFS) for each cohort
- PFS on next line treatment for each cohort
- Percentage of participants overall response rate (ORR) for each cohort
Percentage of participants with clinical benefit rate (CBR) for each cohort
- Duration of response (DOR)

**Key Results**

**Adverse effects (AEs)**

**Expected reporting date**

Estimated primary completion date reported as Jan 2020.

---

**ESTIMATED COST and IMPACT**

**COST**

The cost of alpelisib is not yet known.

Fulvestrant (Falsodex) is marketed in the UK for the treatment of oestrogen-receptor-positive metastatic or locally advanced breast cancer in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy.

The NHS indicative price for 2 pre-filled disposable injection of fulvestrant (Faslodex) 250mg/5ml solution is £522.41.

---

**IMPACT – SPECULATIVE**

**IMPACT ON PATIENTS AND CARERS**

☑ Reduced mortality/increased length of survival ☐ Reduced symptoms or disability

☐ Other ☐ No impact identified

---

**IMPACT ON HEALTH and SOCIAL CARE SERVICES**

☐ Increased use of existing services ☐ Decreased use of existing services

☐ Re-organisation of existing services ☐ Need for new services

☐ Other ☒ None identified

---

**IMPACT ON COSTS and OTHER RESOURCE USE**

☐ Increased drug treatment costs ☐ Reduced drug treatment costs
☐ Other increase in costs  ☐ Other reduction in costs

☒ Other: uncertain unit cost compared to existing treatments  ☐ None identified

OTHER ISSUES

☐ Clinical uncertainty or other research question identified  ☒ None identified

REFERENCES


ClinicalTrials.gov. Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor or fulvestrant (BYLieve): NCT03056755. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03056755 [Accessed 24 October 2017]